Chemokines in inflammatory bowel disease

Research output: Contribution to journalReview article

75 Citations (Scopus)

Abstract

Ulcerative colitis (UC) and Crohn's disease (CD), collectively termed inflammatory bowel diseases (IBD), represent chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract that are charcterized by leukocytic infiltration of the intestinal mucosa and submucosa. In CD, the inflammation is transmural and frequently associated with granuloma formation. Chemokines have emerged as the most important regulators of leukocyte trafficking during infection or inflammation and, therefore, have been implicated in the pathogenesis of IBD. In this review, recent advances on the role of chemokines and their receptors in mucosal immunity and inflammation are discussed, and the potential use of chemokine/chemokine-receptor antagonists as novel therapeutic targets for the treatment of human IBD is highlighted.

Original languageEnglish (US)
Pages (from-to)83-89
Number of pages7
JournalCurrent Allergy and Asthma Reports
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Inflammatory Bowel Diseases
Chemokines
Chemokine Receptors
Inflammation
Crohn Disease
Mucosal Immunity
Intestinal Mucosa
Granuloma
Ulcerative Colitis
Gastrointestinal Tract
Leukocytes
Infection
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Chemokines in inflammatory bowel disease. / Papadakis, Konstantinos.

In: Current Allergy and Asthma Reports, Vol. 4, No. 1, 01.01.2004, p. 83-89.

Research output: Contribution to journalReview article

@article{e7abc26a14b744369a3a75a7a903360a,
title = "Chemokines in inflammatory bowel disease",
abstract = "Ulcerative colitis (UC) and Crohn's disease (CD), collectively termed inflammatory bowel diseases (IBD), represent chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract that are charcterized by leukocytic infiltration of the intestinal mucosa and submucosa. In CD, the inflammation is transmural and frequently associated with granuloma formation. Chemokines have emerged as the most important regulators of leukocyte trafficking during infection or inflammation and, therefore, have been implicated in the pathogenesis of IBD. In this review, recent advances on the role of chemokines and their receptors in mucosal immunity and inflammation are discussed, and the potential use of chemokine/chemokine-receptor antagonists as novel therapeutic targets for the treatment of human IBD is highlighted.",
author = "Konstantinos Papadakis",
year = "2004",
month = "1",
day = "1",
doi = "10.1007/s11882-004-0048-7",
language = "English (US)",
volume = "4",
pages = "83--89",
journal = "Current Allergy and Asthma Reports",
issn = "1529-7322",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Chemokines in inflammatory bowel disease

AU - Papadakis, Konstantinos

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Ulcerative colitis (UC) and Crohn's disease (CD), collectively termed inflammatory bowel diseases (IBD), represent chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract that are charcterized by leukocytic infiltration of the intestinal mucosa and submucosa. In CD, the inflammation is transmural and frequently associated with granuloma formation. Chemokines have emerged as the most important regulators of leukocyte trafficking during infection or inflammation and, therefore, have been implicated in the pathogenesis of IBD. In this review, recent advances on the role of chemokines and their receptors in mucosal immunity and inflammation are discussed, and the potential use of chemokine/chemokine-receptor antagonists as novel therapeutic targets for the treatment of human IBD is highlighted.

AB - Ulcerative colitis (UC) and Crohn's disease (CD), collectively termed inflammatory bowel diseases (IBD), represent chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract that are charcterized by leukocytic infiltration of the intestinal mucosa and submucosa. In CD, the inflammation is transmural and frequently associated with granuloma formation. Chemokines have emerged as the most important regulators of leukocyte trafficking during infection or inflammation and, therefore, have been implicated in the pathogenesis of IBD. In this review, recent advances on the role of chemokines and their receptors in mucosal immunity and inflammation are discussed, and the potential use of chemokine/chemokine-receptor antagonists as novel therapeutic targets for the treatment of human IBD is highlighted.

UR - http://www.scopus.com/inward/record.url?scp=2142822265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142822265&partnerID=8YFLogxK

U2 - 10.1007/s11882-004-0048-7

DO - 10.1007/s11882-004-0048-7

M3 - Review article

C2 - 14680627

AN - SCOPUS:2142822265

VL - 4

SP - 83

EP - 89

JO - Current Allergy and Asthma Reports

JF - Current Allergy and Asthma Reports

SN - 1529-7322

IS - 1

ER -